MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

8.59 -1.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.52

Máximo

8.75

Indicadores-chave

By Trading Economics

Rendimento

27M

32K

Vendas

14M

146M

Margem de lucro

0.022

Funcionários

580

EBITDA

22M

21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+92.53% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

23M

1.9B

Abertura anterior

9.74

Fecho anterior

8.59

Sentimento de Notícias

By Acuity

21%

79%

44 / 376 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de jul. de 2025, 21:01 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 20:46 UTC

Ganhos

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 de jul. de 2025, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 20:36 UTC

Ganhos

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 de jul. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 de jul. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 20:02 UTC

Conversa de Mercado

Gold Higher to Close Out Week -- Market Talk

18 de jul. de 2025, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 de jul. de 2025, 19:06 UTC

Conversa de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 de jul. de 2025, 18:24 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 de jul. de 2025, 18:19 UTC

Ganhos

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 de jul. de 2025, 18:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 de jul. de 2025, 18:11 UTC

Ganhos

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 de jul. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 de jul. de 2025, 16:29 UTC

Conversa de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 de jul. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 16:04 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 de jul. de 2025, 15:47 UTC

Conversa de Mercado
Ganhos

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

92.53% parte superior

Previsão para 12 meses

Média 16.75 USD  92.53%

Máximo 30 USD

Mínimo 11 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

11

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

44 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.